



## Original article

### Pre-stroke Statin use was associated with lower risk of in-hospital death in non-thrombolysed patients

<sup>1</sup>Nazim Dakaj, <sup>1</sup>Argjend Shala, <sup>1,2</sup>Fisni Jashari, <sup>1</sup>Dren Boshnjaku, <sup>2</sup>Dardan Jashari, <sup>1</sup>Granit Xhiha, <sup>2,3</sup>Zylfije Hundozi\*.

<sup>1</sup>Clinic of Neurology, University Clinical Center of Kosovo, Prishtina, Kosovo, 10000.

<sup>2</sup>Faculty of Medicine, University of Prishtina, Prishtina, Kosovo, 10000

#### ABSTRACT

**Background:** Prior studies suggested that statins might have a neuroprotective effect in patients with acute ischemic stroke. The aim of this study was the evaluation of the short-term effects of statins following ischemic stroke among non-thrombolysed patients. **Methods:** In this cohort retrospective study we have included 810 ischemic stroke patients (mean age  $69.7 \pm 11.5$ , 48.6% females), not-thrombolysed on admission. Based on their prior medication history patients were categorized into pre-stroke statin user and non-statin user patients. The risk of in-hospital mortality was compared between two groups. **Results:** Of the 810 ischemic stroke patients, 146 (18.2%) were using a statin before stroke. Statin therapy before stroke-onset was associated with a lower risk of in-hospital mortality (3.4% vs. 26.9%),  $p < 0.001$ . In the multivariable analysis, statin use was independently associated with a favorable outcome (OR = 0.119, 95% CI = 0.047-0.299,  $p < 0.001$ ). **Conclusion:** Prior statin therapy in patients with acute ischemic stroke non-thrombolysed patients is associated with lower risk of in-hospital death, and this is independent of other risk factors.

**KEYWORDS:** Stroke, statins, in-hospital death, mortality

#### INTRODUCTION

Stroke is one of the leading causes of death and a major cause of morbidity worldwide [1]. Atherosclerosis disease and inflammation play important roles in the pathogenesis of acute ischemic stroke [2, 3]. Statins, the 3-hydroxy 3-methyl-glutaryl coenzyme-A (HMG-CoA) reductase inhibitors, are medications originally used for the control of hypercholesterolemia [4]. However, there is increasing evidence showing that statins have some other pleiotropic effects aside from their cholesterol-lowering properties [5]. Statin therapy has been shown to reduce cardiovascular and cerebrovascular events, including myocardial infarction, stroke, and death [6-8].

Several studies using animal models of ischemic stroke showed that statin therapy might have neuroprotective effects when started before or immediately after induction of focal cerebral ischemia [9]. However, the benefits of pre-

stroke statin therapy in patients with acute ischemic stroke remain controversial [10, 11]. Moreover, most of previous studies have included patients treated with tissue plasminogen activator (tPA) on admission. The aim of our study was to evaluate the effects of prior statin therapy early after stroke (in-hospital mortality rate) in a cohort of ischemic stroke patients who do not underwent thrombolysis on admission.

#### MATERIALS AND METHODS

The University Clinical Centre of Kosovo (UCCCK) is the only tertiary health care centre in Kosovo and most of the stroke patients in Kosovo are admitted and treated to the Neurology Clinic, UCCCK. In this study we have retrospectively analyzed data of all of the patients admitted to the hospital from January 1, 2015 to December 31, 2015. Patients with hemorrhagic stroke and those with venous

sinus thrombosis were excluded from the study. None of the patients included in this study have received intravenous or intra-arterial thrombolytic therapy. All patients included in this study have been hospitalized for a period of at least 6 days prior discharge. In total, 1073 patients (mean age 69.12, 51.6% females) with ischemic or hemorrhagic stroke were included in this study. We have previously used the clinical data of this cohort of patients and have already published a paper on another subject, by Hundozi et al. [12].

#### *Patients' clinical data collection*

The diagnosis of stroke was based on direct observation by the medical staff, and also by evaluating clinical signs and analysing imaging (computed tomography (CT) and magnetic resonance imaging (MRI)) results. Blood pressure (BP) on admission was considered to be the average of all readings (median = 2) obtained in the emergency department and admission room before the administration of any antihypertensive drugs. All patients underwent a CT scan within 24 h after admission and a second one within 72 h when necessary.

All patients with ischemic stroke were investigated with carotid Doppler and ECG; most also received transthoracic echocardiography. Prognostic risk factors were assessed for each patient, including age, gender, serum glucose, hypertension (defined as the use of antihypertensive agents, a systolic blood pressure >140 mm Hg or a diastolic blood pressure >90 mm Hg), prior stroke, prior/on-going coronary artery disease, atrial fibrillation, diabetes mellitus, hypercholesterolemia (defined as the use of antihyperlipidaemic agents or a serum cholesterol level >220 mg/dl), current smoking (defined as a history of smoking during the preceding 3 months).

In addition, information about the patient's medication at stroke onset was determined. The morning after admission, fasting blood samples were taken to determine complete blood count (CBC), cholesterol concentration, serum glucose level, and liver and kidney function tests. Data for the early after stroke (in-hospital) mortality was recorded and

compared between patients with and without prior statin therapy.

#### *Statistical analysis*

Categorical variables were expressed as percentages and continuous variables were expressed as the means standard deviations (SD). We used Student's t-test to compare the mean age (continuous variable) between patients in-hospital mortality rate, and for the remaining comparisons, we used the chi-square test with a pre-selected significance level of  $p < 0.05$ . Logistic regression models were used to determine the relationship between pre-stroke statin use and in-hospital mortality rate. In addition, we have performed several models in order to determine the effects of statins on stroke patients' outcome independently of different clinical and demographic data. All statistical analyses were performed using IBM SPSS Statistics 22.

## **RESULTS**

In this study we have included 810 ischemic stroke patients. Mean age was  $69.7 \pm 11.5$  and 48.6% were females. Patients demographics, clinical data and data for their pre-stroke medications used are presented in table 1. Based on their prior medication history patients were categorized into pre-stroke statin user and non- statin user patients.

Of the 810 ischemic stroke patients, 146 (18.2%) were using a statin before stroke. Statin therapy before stroke-onset was associated with a lower risk of in-hospital mortality (3.4% vs. 26.9%),  $p < 0.001$  (table 2). In the multivariable analysis, using different clinical variables as cofounders, pre-stroke statin use was independently associated with a favorable outcome (OR = 0.119, 95% CI = 0.047-0.299,  $p < 0.001$ ) (table 3). In addition, older patients (>65 years) were significantly associated with increased risk of in-hospital mortality after ischemic stroke (table 2 and 3).

**Table 1: Patients' clinical and demographic data**

Patients data	n (%)
Male	421 (51.4)
Female	389 (48.6)
Age, mean (SD)	69.7 (11.5)
Hypertension	547 (68.3)
Diabetes mellitus	194 (24.3)
Cardiomyopathy	103 (13.0)
Atrial fibrillation	47 (5.9)
Dyslipidemia	101 (12.7)
Any anticoaggregation	469 (58.6)
Anticoagulation	51 (6.7)
Statins	146 (18.2)
ACE inhibitors	317 (38.6)

Beta blockers	108 (13.5)
Ca blockers	48 (6.0)
Angiotension receptor blockers	48 (6.0)

**Table 2: Comparison of in-hospital mortality between different patients' clinical features, and pre-stroke statin use**

In-hospital death			
	Yes	No	
Pre-stroke statin use, n(%)			
Yes	5 (3.4)	141 (96.6)	<0.001
No	176 (26.9)	478 (73.1)	
Gender, n (%)			0.611
Male	96 (23.4)	315 (76.6)	
Female	85 (21.3)	304 (78.1)	
Hypertension, n (%)			0.121
Yes	115 (21.1)	431 (78.9)	
No	66 (26)	118 (74.0)	
Age, n (%)			<0.001
<65	37 (13.9)	229 (86.1)	
>65	144 (27.0)	389 (73.0)	
Diabetes mellitus, n (%)			0.2
Yes	37 (19.2)	156 (80.8)	
No	143 (23.6)	463 (76.4)	
Cardiomyopathy, n (%)			0.093
Yes	30 (29.1)	73 (70.9)	
No	115 (21.7)	545 (78.3)	
Atrial fibrillation, n (%)			0.899
Yes	11 (23.4)	36 (76.6)	
No	117 (22.6)	582 (77.4)	
Dyslipidemia, n (%)			0.101
Yes	31 (30.6)	70 (69.4)	
No	116 (17.4)	547 (83.6)	

**Table 3: Regression analysis( Univariable and multivariable using different models).**

	Regression analysis			
	OR	95% CI	Standard error	p-value
Pre-stroke statin use	0.096	(0.019-0.238)	0.45	<0.001

Model 1	0.106	(0.013-0.265)	0.77	<0.001
Model 2	0.108	(0.043-0.268)	0.83	<0.001
Model 3	0.12	(0.048-0.299)	0.84	<0.001
Model 4	0.119	(0.047-0.299)	0.84	<0.001
Gender (female)	0.917	(0.658-1.278)	0.123	0.611
Age (>65)	2.29	(1.541-3.406)	0.098	<0.001
Hypertension	1.316	(0.92-1.86)	0.105	0.122
Diabetes mellitus	1.3	(0.869-1.951)	0.183	0.201
Atrial fibrillation	0.956	(0.476-1.918)	0.345	0.89

*Model 1-pre-stroke statin use, age and gender; Model 2-pre-stroke statin use, age, gender, hypertension; Model 3-prestroke statin use, age, gender, hypertension, diabetes mellitus; Model 4- pre-stroke statin use, age, gender, hypertension, diabetes mellitus and atrial fibrillation*

## DISCUSSION

There is mounting evidence that statin (3-hydroxy-3-methylglutaryl-coenzyme A inhibitors [HMG-CoA]) therapy may alter vascular atherosclerosis and reduce cardiovascular events, including myocardial infarction and stroke [6, 7], with reports published as early as 1994 (4S trial) [13]. However, the decreased risk of stroke could not be explained by inhibition of cholesterol biosynthesis alone. It was determined that in addition to lipid profile improvement; statins also induce some cholesterol-independent, "pleiotropic", effects that contribute to atherosclerotic plaque stabilization.

Indeed, numerous experimental and clinical studies indicated that some of these effects might involve: restoring endothelial function, decreasing oxidative stress and decreasing vascular inflammation [5]. By improving endothelial cell function or restoration, inhibition of secretion of several matrix metalloproteinases (MMPs) by inflammatory cells, inhibition of proliferation and migration of SMC from media to intima, also decreasing vascular inflammation that consists to stability of atherosclerotic plaques [14].

Statins are among the most effective drugs in reducing the risk of stroke. An early meta-analysis [15] showed a significant reduction of stroke risk in patients receiving statins compared to placebo with an overall risk reduction of 31%. The JUPITER study further demonstrates that rosuvastatin significantly reduces the incidence of major cardiovascular events in apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels. Furthermore, the abrupt withdrawal of statin therapy may increase the risk of cardiovascular events and death because of rebound of inflammatory response [16].

Recent studies also show that prior or early use of statins may reduce the severity and improve the outcome of myocardial infarction, ischemic stroke, and intra-cerebral hemorrhage [17-20]. Consistent with previous research, the current study reveals that pre-treatment with statins may be associated with reduced clinical severity and favorable three-month outcome in patients with acute ischemic stroke [18, 19].

Although, pre-stroke treatment showed better outcome compared to placebo in animal models, the effects of pre-stroke statin use on clinical stroke severity and functional outcomes have been inconsistent [21]. In addition, previous studies have evaluated patients that underwent thrombolysis on admission, showing that statin therapy might be associated with slight increase risk of hemorrhage after thrombolysis [22]. According to this, it seems important to evaluate the effects of pre-statin use in stroke patients after excluding patients who received thrombolysis on admission. We suggest that this might explain our study results, showing clear benefit of pre-statin use on stroke outcome, with over 20% absolute risk reduction of in-hospital mortality rate compared to patients who were not receiving statin therapy.

**Limitations:** This is a retrospective study, which presents limitations. One limitation of our study is the lack of information about the dosage of the statins for most patients included. Another limitation is the lack of the data of the infarct size and also the lack of information for the presence and stability of the carotid atherosclerotic plaques, a well-known factor that might influence stroke recurrences among patients with acute ischemic stroke.

## CONCLUSION

Patients that were using statin therapy showed lower in-hospital mortality rate after acute ischemic stroke. These protective effects of statins seem to be independent of the prior comorbidities and patients' clinical data on admission.

**Competing interest:** The authors declare that they have no competing interests.

## REFERENCES

1. Suwanwela N, Koroshetz WJ. Acute ischemic stroke: overview of recent therapeutic developments. *Annu Rev Med.* 2007;58:89-106.

2. Ruggeri ZM. Platelets in atherothrombosis. *Nat Med*. 2002 Nov;8(11):1227-34.
3. Jashari F, Ibrahim P, Nicoll R, Bajraktari G, Wester P, Henein MY. Coronary and carotid atherosclerosis: similarities and differences. *Atherosclerosis*. 2013 Apr;227(2):193-200.
4. Alberts AW. Discovery, biochemistry and biology of lovastatin. *Am J Cardiol*. 1988 Nov 11;62(15):10J-15J.
5. Kwak BR, Mach F. Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. *Arterioscler Thromb Vasc Biol*. 2001 Aug;21(8):1256-8.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med*. 1998 Nov 5;339(19):1349-57.
7. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. *Stroke*. 2005 Jun;36(6):1298-300.
8. Amarenco P, Goldstein LB, Szarek M, Silleisen H, Rudolph AE, Callahan A. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. *Stroke*. 2007 Dec;38(12):3198-204.
9. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. *Brain Res*. 2002 Jun 28;942(1-2):23-30.
10. Tsai NW, Lin TK, Chang WN, Jan CR, Huang CR, Chen SD. Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke. *Crit Care*. 2011 Jul 8;15(4):R163.
11. Ishikawa H, Wakisaka Y, Matsuo R, Makihara N, Hata J, Kuroda J. Influence of Statin Pretreatment on Initial Neurological Severity and Short-Term Functional Outcome in Acute Ischemic Stroke Patients: The Fukuoka Stroke Registry. *Cerebrovasc Dis*. 2016 Jul 5;42(5-6):395-403.
12. Hundozi Z, Shala A, Boshnjaku D, Bytyqi S, Rustemi J, Rama M, Jashari F. Hypertension on admission is associated with a lower risk of early seizures after stroke. *Seizure*. 2016 Mar;36:40-3.
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994 Nov 19;344(8934):1383-9.
14. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. *J Leukoc Biol*. 2001 Jun;69(6):959-62.
15. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. *Stroke*. 1997 May;28(5):946-50.
16. Li JJ, Li YS, Chen J, Yang JQ: Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. *Med Hypotheses* 2006; 66:1199-1204.
17. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ: Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. *Am J Cardiol* 2005; 96:611-616.
18. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, Cocho D, Roquer J, Rodriguez A, Garcia M, Molina-Porcel L, Díaz-Manera J, Martí-Vilalta J-L: Favorable outcome of ischemic stroke in patients pretreated with statins. *Stroke* 2004; 35:1117-1121.
19. Greisenegger S, Mullner M, Tentschert S, Lang W, Lalouschek W: Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. *J Neurol Sci* 2004; 221:5-10.
20. Leker RR, Khoury ST, Rafaeli G, Schwartz R, Eichel R, Tanne D: Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). *Stroke* 2009; 40:2581-2584.
21. Hong KS, Lee JS. Statins in Acute Ischemic Stroke: A Systematic Review. *J Stroke*. 2015 Sep;17(3):282-301.
22. Scheitz JF, Seiffge DJ, Tütüncü S, Gensicke H, Audebert HJ, Bonati LH, et al. Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. *Stroke*. 2014 Feb;45(2):509-14.

---

\*Corresponding author: Prof. Dr. Zulfije Hundozi  
E-Mail: [zhundozi@hotmail.com](mailto:zhundozi@hotmail.com)